<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Orphanet J Rare Dis</journal-id><journal-id journal-id-type="iso-abbrev">Orphanet J Rare Dis</journal-id><journal-title-group><journal-title>Orphanet Journal of Rare Diseases</journal-title></journal-title-group><issn pub-type="epub">1750-1172</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4573700</article-id><article-id pub-id-type="publisher-id">336</article-id><article-id pub-id-type="doi">10.1186/s13023-015-0336-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Ichthyosis with confetti: clinics, molecular genetics and management</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Guerra</surname><given-names>Liliana</given-names></name><address><email>l.guerra@idi.it</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Diociaiuti</surname><given-names>Andrea</given-names></name><address><email>andrea.diociaiuti@opbg.net</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>El Hachem</surname><given-names>May</given-names></name><address><email>may.elhachem@opbg.net</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Castiglia</surname><given-names>Daniele</given-names></name><address><email>d.castiglia@idi.it</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Zambruno</surname><given-names>Giovanna</given-names></name><address><phone>+39 333 716 4866</phone><email>giovanna.zambruno@gmail.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><label/>Laboratory of Molecular and Cell Biology, Istituto Dermopatico dell&#8217;Immacolata-IRCCS, Rome, Italy </aff><aff id="Aff2"><label/>Dermatology Unit, Bambino Ges&#249; Children&#8217;s Hospital-IRCCS, Rome, Italy </aff></contrib-group><pub-date pub-type="epub"><day>17</day><month>9</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>17</day><month>9</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>10</volume><elocation-id>115</elocation-id><history><date date-type="received"><day>6</day><month>6</month><year>2015</year></date><date date-type="accepted"><day>1</day><month>9</month><year>2015</year></date></history><permissions><copyright-statement>&#169; Guerra et al. 2015</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><p>Ichthyosis with confetti (IWC) is an autosomal dominant congenital ichthyosis also known as ichthyosis variegata or congenital reticular ichthyosiform erythroderma. It manifests at birth with generalized ichthyosiform erythroderma or with a collodion baby picture. The erythrodermic and ichthyotic phenotype persists during life and its severity may modify. However, the hallmark of the disease is the appearance, in childhood or later in life, of healthy skin confetti-like spots, which increase in number and size with time. IWC is a very rare genodermatosis, with a prevalence &lt;1/1,000,000 and only 40 cases reported worldwide. The most important associated clinical features include ear deformities, mammillae hypoplasia, palmoplantar keratoderma, hypertrichosis and ectropion. IWC is due to dominant negative mutations in the <italic>KRT10</italic> and <italic>KRT1</italic> genes, encoding for keratins 10 and keratin 1, respectively. In this context, healthy skin confetti-like spots represent &#8220;repaired&#8221; skin due to independent events of reversion of keratin gene mutations via mitotic recombination. In most cases, IWC clinical suspicion is delayed until the detection of white skin spots. Clinical features, which may represent hint to the diagnosis of IWC even before appearance of confetti-like spots, include ear and mammillae hypoplasia, the progressive development of hypertrichosis and, in some patients, of adherent verrucous plaques of hyperkeratosis. Altogether the histopathological finding of keratinocyte vacuolization and the nuclear staining for keratin 10 and keratin 1 by immunofluorescence are pathognomonic. Nevertheless, mutational analysis of <italic>KRT10</italic> or <italic>KRT1</italic> genes is at present the gold standard to confirm the diagnosis. IWC has to be differentiated mainly from congenital ichthyosiform erythroderma. Differential diagnosis also includes syndromic ichthyoses, in particular Netherton syndrome, and the keratinopathic ichthyoses. Most of reported IWC cases are sporadic, but familial cases with autosomal dominant mode of inheritance have been also described. Therefore, knowledge of the mutation is the only way to properly counsel the couples. No specific and satisfactory therapy is currently available for IWC. Like for other congenital ichthyoses, topical treatments (mainly emollients and keratolytics) are symptomatic and offer only temporary relief. Among systemic treatments, retinoids, in particular acitretin, improve disease symptoms in most patients. Although at present there is no curative therapy for ichthyoses, treatments have improved considerably over the years and the best therapy for each patient is always the result of both physician and patient efforts.</p><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1186/s13023-015-0336-4) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Ichthyosis with confetti</kwd><kwd>Ichthyosis variegata</kwd><kwd>Congenital reticular ichthyosiform erythroderma</kwd><kwd>Mammillae hypoplasia</kwd><kwd>Ear hypoplasia</kwd><kwd>Keratin 10</kwd><kwd>Keratin 1</kwd><kwd>Revertant skin</kwd><kwd>Loss of heterozygosity</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; The Author(s) 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Review</title><sec id="Sec2"><title>Disease name/synonyms</title><p>Ichthyosis with confetti</p><p>Congenital reticular ichthyosiform erythroderma</p><p>Ichthyosis variegata</p><p>Orphanumber: ORPHA281190</p><p>OMIM: 609165</p></sec><sec id="Sec3"><title>Definition</title><p>Ichthyosis with confetti (IWC) [<xref ref-type="bibr" rid="CR1">1</xref>] is an autosomal dominant congenital ichthyosis also known as ichthyosis variegata [<xref ref-type="bibr" rid="CR2">2</xref>] or congenital reticular ichthyosiform erythroderma (CRIE) [<xref ref-type="bibr" rid="CR3">3</xref>], the latter being the disease name recommended in the clinical-genetic classification of inherited ichthyoses, developed by the First Ichthyosis Consensus Conference in 2009 [<xref ref-type="bibr" rid="CR4">4</xref>]. According to the current classification, IWC belongs to non-syndromic ichthyoses [<xref ref-type="bibr" rid="CR4">4</xref>]. IWC manifests at birth with generalized ichthyosiform erythroderma [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR5">5</xref>&#8211;<xref ref-type="bibr" rid="CR16">16</xref>] or with a collodion baby picture [<xref ref-type="bibr" rid="CR17">17</xref>&#8211;<xref ref-type="bibr" rid="CR19">19</xref>]. The hallmark of this form of ichthyosis is the appearance, in childhood or later in life, of confetti-like spots of pale and normal-appearing skin, which increase in number and size with time [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR5">5</xref>&#8211;<xref ref-type="bibr" rid="CR19">19</xref>].</p></sec></sec><sec id="Sec4" sec-type="methods"><title>Methods</title><p>A literature search was performed on PubMed from 1984, when IWC was first described, to April 30, 2015. In addition, the Orphanet database [<xref ref-type="bibr" rid="CR20">20</xref>] was looked at. The following search terms were used: &#8220;ichthyosis with confetti&#8221;, &#8220;congenital reticular ichthyosiform erythroderma&#8221;, &#8220;ichthyosis variegata&#8221;, &#8220;MAUIE syndrome&#8221;. We then checked the bibliography of each article to identify additional references. Altogether, 17 reports containing a total of 40 IWC cases were identified.</p><sec id="Sec5"><title>Epidemiology</title><p>IWC is a very rare genodermatosis, with a prevalence &lt;1/1,000,000 [<xref ref-type="bibr" rid="CR20">20</xref>]. To our knowledge, only 40 IWC cases have been reported (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR5">5</xref>&#8211;<xref ref-type="bibr" rid="CR19">19</xref>]. The disease may be underdiagnosed as 9 cases have been described between 1984 and 2010 [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR10">10</xref>&#8211;<xref ref-type="bibr" rid="CR12">12</xref>], while ten cases have been collected by Choate et al. who deciphered the causative gene in 2010 [<xref ref-type="bibr" rid="CR13">13</xref>] and 21 additional cases have been reported since then [<xref ref-type="bibr" rid="CR15">15</xref>&#8211;<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR19">19</xref>].<table-wrap id="Tab1"><label>Table 1</label><caption><p>Clinical findings in 40 reported cases of ichthyosis with confetti</p></caption><table-wrap-foot><p>Most reported clinical findings: <italic>CB/CIE</italic> colloidon baby/congenital ichthyosiform erythroderma; <italic>HSS</italic> healthy skin spots; <italic>S/HK</italic> scaling/hyperkeratosis; <italic>EM</italic> ear malformation; <italic>MH</italic> mammillae hypoplasia; <italic>PPK</italic> palmoplantar keratoderma; <italic>DAH</italic> dorsal acral hypertrichosis; <italic>EE</italic> eyelid ectropion; + present; &#8722; absent</p><p>Additional findings: <italic>AU</italic> alopecia universalis; <italic>DFL</italic> decreased finger length (relative to palm). <italic>DHL</italic> diffuse hair loss; <italic>E</italic> eclabion; <italic>GA</italic> gait abnormality due to joint contractions of the limbs; <italic>GH</italic> generalized hypertrichosis; <italic>HES</italic> hyperpigmentation on erythrokeratotic skin; <italic>HHSS</italic> hyperpigmentation in healthy skin spots; <italic>JCF</italic> joint contractions of the fingers; <italic>LL/LNP</italic> large lunulae/ long nail plates; <italic>N</italic> nystagmus; <italic>NMSC</italic> nonmelanoma skin cancer; <italic>P</italic> pruritus. <italic>PH</italic> peripheral hyperreflexia; <italic>PR</italic> psychomotor retardation; <italic>REE</italic> reduced eyebrows and eyelashes; <italic>S</italic> strabismus; <italic>SI</italic> scalp involvement; <italic>SS/LW</italic> short stature/ low weight (relative to age); <italic>UI</italic> unguis inflexus; <italic>NR</italic> not reported. <italic>NP</italic> not performed</p><p>
<sup>a</sup>Camenzind et al. [<xref ref-type="bibr" rid="CR1">1</xref>] reported a second IWC patient (patient 32 in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>) who was further described by Brusasco et al. [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR9">9</xref>] and Spoerri et al. [<xref ref-type="bibr" rid="CR19">19</xref>]</p><p>
<sup>b</sup>Elbaum et al. [<xref ref-type="bibr" rid="CR7">7</xref>] and Hendrix et al. [<xref ref-type="bibr" rid="CR8">8</xref>] reported two patients with a disease classified as MAUIE syndrome that shared almost all clinical findings with IWC</p><p>
<sup>c</sup>Additional clinical data of patients first described by Diociaiuti et al. [<xref ref-type="bibr" rid="CR17">17</xref>]</p><p>
<sup>d</sup>Monozygotic twin sister of patient 35, with a very similar phenotype</p><p>
<sup>e</sup>Affected offsprings of patient 37</p><p>
<sup>f</sup>MH is visible on published pictures of Marghescu et al. [<xref ref-type="bibr" rid="CR3">3</xref>] and Krunic et al. [<xref ref-type="bibr" rid="CR12">12</xref>]</p><p>
<sup>g</sup>a 11&#160;years old female was clinically characterized by Long [<xref ref-type="bibr" rid="CR18">18</xref>]</p><p>
<sup>h</sup>symptoms reported by Choate et al. [<xref ref-type="bibr" rid="CR15">15</xref>] in a IWC cohort of 20 patients all carrying <italic>KRT10</italic> mutations</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec6"><title>Clinical description</title><p>IWC manifests at birth as a non-bullous generalized ichthyosiform erythroderma [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR10">10</xref>&#8211;<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR19">19</xref>] or as a collodion baby [<xref ref-type="bibr" rid="CR17">17</xref>&#8211;<xref ref-type="bibr" rid="CR19">19</xref>]. The collodion membrane is typically shed within the first days of life [<xref ref-type="bibr" rid="CR17">17</xref>&#8211;<xref ref-type="bibr" rid="CR19">19</xref>]. The erythrodermic and ichthyotic phenotype (Fig.&#160;<xref rid="Fig1" ref-type="fig">1a</xref>&#8211;<xref rid="Fig1" ref-type="fig">d</xref>) persists during life, even if its severity may modify [<xref ref-type="bibr" rid="CR19">19</xref>]. In addition, the extent and type of scaling and hyperkeratosis vary significantly, ranging from white fine scales [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>], highly reminiscent of congenital ichthyosiform erythroderma, to verrucous hyperkeratotic adherent plaques more evident on the limbs [<xref ref-type="bibr" rid="CR17">17</xref>] (Fig.&#160;<xref rid="Fig1" ref-type="fig">1a</xref>&#8211;<xref rid="Fig1" ref-type="fig">c</xref>). Of note, with time patients develop confetti-like spots of healthy skin (Fig.&#160;<xref rid="Fig1" ref-type="fig">1d</xref>&#8211;<xref rid="Fig1" ref-type="fig">e</xref>) on the erythrodermic background. These are the hallmark of the disease and frequently suggest the correct diagnosis. Spots start appearing during childhood, gradually increase in number to hundreds [<xref ref-type="bibr" rid="CR13">13</xref>] and enlarge from 2 to 10&#160;mm up to 4&#160;cm in diameter [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. Sometimes, they are recognized only after hyperkeratosis shedding due to retinoid therapy [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. The spots are regularly present on the trunk [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>] and may spread to limbs and the rest of the body. Healthy spots seem to follow a distribution gradient across the skin, being largest and more numerous on the neck, d&#233;collet&#233; and scapula regions, fewer and smaller on arms and legs, and rare on the face [<xref ref-type="bibr" rid="CR19">19</xref>]. Moreover, they have been described either as depressed [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR11">11</xref>] or slightly elevated [<xref ref-type="bibr" rid="CR6">6</xref>] with respect to the surrounding skin. Due to the presence of many, at instance confluent, confetti-like spots, the adjacent ichthyotic skin may assume a reticulate pattern [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. Of note, a later age at first appearance of confetti-like spots (22&#160;years), a smaller size (maximum 4&#160;mm) and a predominant involvement of flexures characterize the recently described IWC-II subtype [<xref ref-type="bibr" rid="CR16">16</xref>].<fig id="Fig1"><label>Fig. 1</label><caption><p>Major clinical features of ichthyosis with confetti. Severe ichthyosiform erythroderma: massive verrucous hyperkeratosis on the buttocks (<bold>a</bold>), knees (<bold>b</bold>) and feet (<bold>c</bold>) in the absence of retinoid therapy. Confetti-like spots of healthy skin are visible on the trunk and cheek (<bold>d</bold>, <bold>e</bold>: <italic>black rings</italic>) of the same patient. Note the presence of mammillae hypoplasia (<bold>d</bold>, <italic>arrowheads</italic>). Ear malformations: hypoplasia of the ear helix (<bold>e</bold>, <bold>f</bold>), and lobule (<bold>e</bold>). Clinical pictures are from a 8-year-old male (<bold>a</bold>-<bold>e</bold>) and a 1-year-old female (<bold>f</bold>)</p></caption><graphic xlink:href="13023_2015_336_Fig1_HTML" id="MO1"/></fig></p><p>Table&#160;<xref rid="Tab1" ref-type="table">1</xref> summarizes all the clinical features, when described, in previously reported IWC patients. Ectodermal malformations, specifically ear deformities (Fig.&#160;<xref rid="Fig1" ref-type="fig">1e</xref>&#8211;<xref rid="Fig1" ref-type="fig">f</xref>) and mammillae hypoplasia (Figs.&#160;<xref rid="Fig1" ref-type="fig">1d</xref> and <xref rid="Fig2" ref-type="fig">2a</xref>) are typical of IWC patients [<xref ref-type="bibr" rid="CR17">17</xref>&#8211;<xref ref-type="bibr" rid="CR19">19</xref>]. Ear deformities, comprising micropinna (small ears and external auditory canal) and, in a more general way, ear hypoplasia, are already evident at birth [<xref ref-type="bibr" rid="CR18">18</xref>]. Mammillae hypoplasia has been only reported by Spoerri et al. [<xref ref-type="bibr" rid="CR19">19</xref>]. However, it can be underestimated as Spoerri noticed that it seems visible on previous published pictures of some IWC patients [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR12">12</xref>] and a reevaluation of our two patients [<xref ref-type="bibr" rid="CR17">17</xref>] confirmed its presence (Figs.&#160;<xref rid="Fig1" ref-type="fig">1d</xref> and <xref rid="Fig2" ref-type="fig">2a</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p>Major and minor clinical features of ichthyosis with confetti. Mammillae hypoplasia (<bold>a</bold>, <italic>arrowheads</italic>), palmoplantar hyperkeratosis (<bold>b</bold>), hypertrichosis of acral dorsal areas (<italic>arrowheads</italic>) (<bold>c</bold>) and back (<bold>d</bold>), scaling and hyperkeratosis of the scalp (<bold>e</bold>), large lunulae (<bold>f</bold>), long nail plates and unguis inflexus (<bold>g</bold>), severe eyelid ectropion (<bold>h</bold>). Clinical pictures are taken from a female at the age of 1&#160;year (<bold>b</bold>, <bold>e,</bold>
<bold>f</bold>), 2.5 (<bold>c</bold>) and 2.7&#160;years (<bold>a</bold>, <bold>d</bold>) and a male at the age of 5 (<bold>g</bold>) and 8 (<bold>h</bold>) years. Note the healthy skin confetti-like spots (<bold>a</bold>, <bold>d</bold>: <italic>black rings</italic>) which became evident after hyperkeratosis shedding due to retinoid therapy</p></caption><graphic xlink:href="13023_2015_336_Fig2_HTML" id="MO2"/></fig></p><p>Palmoplantar keratoderma (PPK) is associated with most IWC cases (Fig.&#160;<xref rid="Fig2" ref-type="fig">2b</xref>) [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR10">10</xref>&#8211;<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR17">17</xref>&#8211;<xref ref-type="bibr" rid="CR19">19</xref>]. It may be characterized by an orange-red color [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR12">12</xref>], increased palmar skin marks [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR18">18</xref>] and absent finger dermatoglyphs [<xref ref-type="bibr" rid="CR14">14</xref>]. Disproportionately severe PPK compared with body hyperkeratosis has been reported in the IWC-II subtype [<xref ref-type="bibr" rid="CR16">16</xref>].</p><p>Hyperpigmented, irregular-shaped macules on the erythrokeratotic skin have been reported in a few cases [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. More frequently, hyperpigmentation within healthy skin spots has been described [<xref ref-type="bibr" rid="CR19">19</xref>].</p><p>Hypohidrosis with temperature intolerance [<xref ref-type="bibr" rid="CR18">18</xref>] and pruritus [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR19">19</xref>] are likely due to the ichthyosiform skin condition.</p><p>Hypertrichosis is a frequent and characteristic IWC sign [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. It can be apparent already in early childhood, and is preferentially localized to dorsal acral areas (Fig.&#160;<xref rid="Fig2" ref-type="fig">2c</xref>) [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR19">19</xref>], with long hair even on the back of hands and fingers [<xref ref-type="bibr" rid="CR14">14</xref>], but can be generalized (Fig.&#160;<xref rid="Fig2" ref-type="fig">2d</xref>) [<xref ref-type="bibr" rid="CR17">17</xref>]. Hypertrichosis is confined to areas of ichthyotic skin [<xref ref-type="bibr" rid="CR19">19</xref>] and never present in confetti-like spots [<xref ref-type="bibr" rid="CR14">14</xref>]. Scaling usually also involves the scalp (Fig.&#160;<xref rid="Fig2" ref-type="fig">2e</xref>) [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR19">19</xref>], sometimes causing alopecia [<xref ref-type="bibr" rid="CR19">19</xref>]. IWC patients may show reduced eyebrows and eyelashes [<xref ref-type="bibr" rid="CR19">19</xref>] and diffuse hair loss [<xref ref-type="bibr" rid="CR11">11</xref>]. Scalp hair heterochromia has been reported [<xref ref-type="bibr" rid="CR14">14</xref>].</p><p>Nails may appear thickened [<xref ref-type="bibr" rid="CR18">18</xref>], with elongated nail plates and enlarged lunulae (Fig.&#160;<xref rid="Fig2" ref-type="fig">2f</xref>) [<xref ref-type="bibr" rid="CR19">19</xref>]. Subungual hyperkeratosis may induce nail curving (Fig.&#160;<xref rid="Fig2" ref-type="fig">2g</xref>) [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>], the so called &#8220;unguis inflexus&#8221; [<xref ref-type="bibr" rid="CR19">19</xref>].</p><p>Other frequent manifestations of IWC are eclabion (outward lip eversion) and ectropion (out turning of the eyelids) (Fig.&#160;<xref rid="Fig2" ref-type="fig">2h</xref>) [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR17">17</xref>&#8211;<xref ref-type="bibr" rid="CR19">19</xref>]. Additional but rarely reported signs of eye involvement are strabismus and nystagmus [<xref ref-type="bibr" rid="CR19">19</xref>].</p><p>Finger length relative to palms may be decreased [<xref ref-type="bibr" rid="CR19">19</xref>]. Joint contractions of the fingers, caused by marked hyperkeratosis, worsen mobility of the hands [<xref ref-type="bibr" rid="CR19">19</xref>]. Tautness of the skin may also involve elbows, shoulders, hips and knees, thus resulting in a forced limb flexion and motor impairment with gait abnormality [<xref ref-type="bibr" rid="CR16">16</xref>&#8211;<xref ref-type="bibr" rid="CR19">19</xref>].</p><p>Almost all IWC individuals have small height and weight for age [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR19">19</xref>], but usually normal neural development. However, peripheral hyperreflexia has been detected by neurologic examination in four patients [<xref ref-type="bibr" rid="CR15">15</xref>] and psychomotor retardation has been reported in one case [<xref ref-type="bibr" rid="CR17">17</xref>]. Multiple non-melanoma skin cancers (NMSCs) have been described in three adult IWC patients [<xref ref-type="bibr" rid="CR15">15</xref>].</p><p>The majority of IWC manifestations are present in the two previously reported cases of MAUIE (micropinnae, alopecia universalis, congenital ichthyosis and ectropion) syndrome (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>, cases 3 and 4) [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. These patients showed congenital ichthyosiform erythroderma at birth, normal-appearing skin spots, ear deformity (micropinna or external ear hypoplasia), ectropion, eclabion and nail thickening [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. At the time of examination, the two adult men also presented a complete absence of hair all over the body [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. NMSCs were additional findings in both cases [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. Although not further characterized, these patients may be considered suffering from IWC [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR15">15</xref>].</p><p>Spoerri et al. [<xref ref-type="bibr" rid="CR19">19</xref>] analysed a cohort of 6 unrelated, genetically characterized, IWC patients and suggested that clinical features of the disease may be grouped into major and minor criteria for diagnosis. Major criteria include all symptoms that the Authors identified as constantly associated with IWC in their cohort, i.e. erythroderma since birth, confetti-like spot appearance, scaling with changing severity, dorsal acral hypertrichosis, hypoplasia of mammillae and malformation of ears. Clinical features which were not always present in every patient were considered as minor criteria. Based on literature data (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>), palmoplantar keratoderma and ectropion appear as frequent as the major clinical findings identified by Spoerri et al. [<xref ref-type="bibr" rid="CR19">19</xref>].</p></sec><sec id="Sec7"><title>Aetiology</title><p>IWC is a disorder of keratins. Keratins are major structural proteins of epithelial cells. They are obligate heterodimers of an acidic type I and neutral-basic type II polypeptide [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. Keratins have a characteristic expression patterns in normal human epithelial tissues according to the function and body site of each cell type. Some of them can have a very restricted tissue-specificity [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. For example, differentiating keratinocytes of the epidermis express a particular pair of type I and type II cytokeratins, keratin 10 (K10) and keratin 1 (K1) [<xref ref-type="bibr" rid="CR25">25</xref>]. All keratins share a common structure composed of a central rod domain, through which they interact to form dimers, flanked by a N- (head) and C-terminal (tail) domain, which are important for elongation and lateral alignment of K1/K10 heterodimers [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. The C-terminal &#8220;tail domain&#8221; of K1 and K10 is unusually glycine rich. In addition, the K10 tail shows extensive size polymorphism due to variable numbers and sizes of glycine loops [<xref ref-type="bibr" rid="CR27">27</xref>]. K1/K10 heterodimers assemble to form the intermediate filaments (IF) cytoskeleton of differentiating epidermal keratinocytes [<xref ref-type="bibr" rid="CR21">21</xref>].</p><p>IWC is due to dominant negative mutations in the K10 gene, <italic>KRT10</italic>, which maps to chromosome 17q21.2 and consists of 8 exons. The large majority of the 13 <italic>KRT10</italic> mutations identified so far represent <italic>de novo</italic> events. All the mutations are single nucleotide substitutions or small insertions and deletions located in exon 6, intron 6 splice sites and exon 7 (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. Of note, each mutation results in a C-terminal frameshift that converts the glycine/serine-rich K10 tail to an arginine-rich carboxy-terminal sequence [<xref ref-type="bibr" rid="CR13">13</xref>]. As arginine-rich motifs are positively charged and encode nuclear localization sequences leading to nuclear entry, mutant K10, and its natural partner K1, accumulates within the nucleus, specifically within nucleoli, which are site of active synthesis of ribosomal RNA [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR15">15</xref>].</p><p>Choate et al. [<xref ref-type="bibr" rid="CR16">16</xref>] have recently described a new IWC subtype, named IWC-II or IWC-K1, due to a heterozygous <italic>de novo</italic> single base-pair insertion in the last exon of K1 gene (<italic>KRT1</italic>) which maps to chromosome 12q13.13. Similarly to <italic>KRT10</italic> gene defects, the <italic>KRT1</italic> mutation introduces a C-terminal frameshift, which results in the replacement of the last 22 K1 aminoacids by a novel 30-aminoacid peptide. In both IWC subtypes the frameshift peptide is implicated in the dominant negative effect that disrupts the interactions of K1/K10 tails, leading to the collapse of IF network and mislocalization of the mutant proteins to the nucleus [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR16">16</xref>].</p><p>Of note, the <italic>KRT10</italic> gene mutations identified in the germline of IWC patients are not found in the DNA extracted from the &#8220;confetti-like&#8221; spots [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. Spots are not visible at birth, appear and expand over time, and have normal tissue architecture. Such observations led Choate et al. to investigate white spot-purified DNA using high-density single nucleotide polymorphism genotyping platforms [<xref ref-type="bibr" rid="CR13">13</xref>]. In paired analysis with blood-purified genomic DNA, each DNA sample from 28 white spots taken from six independent individuals showed homozygous genotypes of a single region of chromosome 17q with copy number equals to two, indicating loss-of-heterozygosity (LOH). The delineated LOH intervals span from a proximal breakpoint to the telomere and varied among samples. However they overlapped and identified the proximal boundary of the <italic>KRT10</italic> locus. Thus, white spots represent &#8220;repaired&#8221; skin due to independent events of reversion of <italic>KRT10</italic> mutations via mitotic recombination (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>). Since white spots can be hundreds and expand over time, the recombination event is expected to occur at a high frequency and to confer selective growth advantage to revertant cell clones. A similar copy-neutral mechanism of genetic recombination was discovered in IWC-II. In this subtype the revertant tissue DNA from several revertant spots harbors overlapping LOH intervals on chromosome 12 with breakpoints proximal to the <italic>KRT1</italic> locus, indicating frequent somatic reversion of the <italic>KRT1</italic> mutation via mitotic recombination [<xref ref-type="bibr" rid="CR16">16</xref>].<fig id="Fig3"><label>Fig. 3</label><caption><p>Schematic of the copy-neutral mechanism of mitotic recombination leading to revertant mosaicism in a patient affected with ichthyosis with confetti. The patient is heterozygous for a pathogenic mutation in the <italic>KRT10</italic> locus (17q21.2, indicated by a horizontal bar within the long arm of the chromosome). During somatic cell division, the parental affected keratinocyte bears homologous chromosomes with wild-type (wt) and mutant (mut) genotypes (<bold>a</bold>). Following a crossover event proximal to the <italic>KRT10</italic> locus both homologous chromosomes will have one chromatid carrying each genotype (<bold>b</bold>). Then, daughter cells receiving the same allele will be homozygous at that locus for either wild-type (revertant cell) or mutant (affected cell) genotype (<bold>c</bold>). A single revertant daughter cell will expand and give rise to the &#8220;confetti-like&#8221; skin spot</p></caption><graphic xlink:href="13023_2015_336_Fig3_HTML" id="MO3"/></fig></p></sec><sec id="Sec8"><title>Diagnosis</title><p>IWC diagnosis is based on dermatologic evaluation, and personal and family history. Skin manifestations, in particular the presence of verrucous hyperkeratotic plaques and associated findings such as ear and mammillae hypoplasia and hypertrichosis, should be carefully evaluated. However, IWC clinical suspicion is usually delayed until the detection of white skin spots. In addition, family history is rarely informative, as most cases are sporadic. Laboratory analyses are mandatory to confirm the diagnosis and represent the only mean to assess it before the appearance of healthy skin macules.</p><p>At first, biopsy should be taken for histological examination from affected skin. Histopathologically, the ichthyotic skin in IWC shows the following alterations of the epidermis: hyperkeratosis with focal parakeratosis (retention of cell nuclei in the stratum corneum), a reduced granular layer and pronounced perinuclear vacuolization of scattered keratinocytes in the suprabasal epidermal layers (Fig.&#160;<xref rid="Fig4" ref-type="fig">4a</xref>, <xref rid="Fig4" ref-type="fig">b</xref>) [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. The presence of binucleated keratinocytes has also been reported [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. IWC-II skin shows a thickened stratum corneum without parakeratosis, milder perinuclear vacuolization with rare binucleated cells and prominent coarse keratohyalin granules, the latter being absent in the classical IWC form [<xref ref-type="bibr" rid="CR16">16</xref>]. On the other hand, a skin biopsy taken within a spot of normal appearing skin always reveals normal architecture. Overall, the histopathological findings of IWC, and in particular the presence of keratinocyte vacuolization, are characteristic and should prompt further diagnostic investigations. Specifically, immunopathological analysis of K10 and K1 expression in the epidermis should be performed. This is carried out by immunofluorescence labelling on formalin-fixed, paraffin-embedded skin sections with commercially available monoclonal antibodies to K10 and K1.<fig id="Fig4"><label>Fig. 4</label><caption><p>Histology and immunofluorescence findings in ichthyosis with confetti caused by <italic>KRT10</italic> mutation. The epidermis appears acanthotic and hyperkeratotic with parakeratosis, a reduced granular layer and cytoplasmic vacuolization in suprabasal keratinocytes (<bold>a</bold>). Higher magnification of the inset depicted in panel (<bold>a</bold>) highlighting the perinuclear vacuolization in suprabasal keratinocytes (<bold>b</bold>). Immunofluorescence labelling for keratin 10 (K10) shows reduced cytoplasmic staining in epidermal suprabasal cell layers, dot-like labelling of numerous nuclei in suprabasal epidermis and bright perinuclear rings (<bold>c</bold>). Higher magnification of the inset depicted in panel <bold>c</bold> showing that nuclear labeling is mainly localised to nucleoli (<bold>d</bold>). Haematoxylin-eosin staining (<bold>a</bold> and <bold>b</bold>), original magnification&#8201;&#215;&#8201;200 (<bold>a</bold>). Nuclear DAPI counterstaining (<bold>c</bold> and <bold>d</bold>), original magnification&#8201;&#215;&#8201;200 (<bold>c</bold>)</p></caption><graphic xlink:href="13023_2015_336_Fig4_HTML" id="MO4"/></fig></p><p>Immunofluorescence labelling for K10 in IWC shows a marked reduction of the cytoplasmic staining in epidermal suprabasal cell layers, collapsed filament networks visible as bright perinuclear rings in scattered keratinocytes and a dot-like labelling of numerous nuclei in suprabasal epidermis (Fig.&#160;<xref rid="Fig4" ref-type="fig">4c</xref>, <xref rid="Fig4" ref-type="fig">d</xref>), while in the healthy control skin K10 is only localized to the keratinocyte cytoplasm [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. Similar findings have also been described for the partner keratin, K1 [<xref ref-type="bibr" rid="CR13">13</xref>]. Counterstaining with the nucleolar markers fibrillarin shows that K10 and also K1 localize to the nucleolus [<xref ref-type="bibr" rid="CR13">13</xref>]. Immunofluorescence labelling for K1 in the IWC-II subtype reveals perinuclear rings in affected skin [<xref ref-type="bibr" rid="CR16">16</xref>]. The nuclear staining for K10 has been described only in IWC epidermis and can be considered a diagnostic hallmark. In addition, K10 immunolabelling performed on archival skin biopsies can allow retrospective diagnosis [<xref ref-type="bibr" rid="CR17">17</xref>].</p><p>At the ultrastructural level, the most significant findings in IWC are the presence of binuclear keratinocytes and cup- or bowl-like perinuclear masses of granular material in the vacuolized superficial keratinocytes [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. A closer examination demonstrates that this material is composed by thin interlacing filaments [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. Additional electron microscopy abnormalities include marked reduction in the total number of keratin tonofilaments in cytoplasm, poorly formed desmosomes and sparse and tapered bundles of keratin filaments attached to desmosomes [<xref ref-type="bibr" rid="CR13">13</xref>].</p><p>Altogether, histopathological and immunofluorescence findings of IWC are pathognomonic. Electron microscopy may further support the diagnosis. Finally, mutational analysis of <italic>KRT10</italic> and <italic>KRT1</italic> genes is at present the gold standard to confirm IWC diagnosis and provides a firm basis for genetic counseling of affected individuals and families. Figure&#160;<xref rid="Fig5" ref-type="fig">5</xref> summarizes the proposed diagnostic algorithm for IWC.<fig id="Fig5"><label>Fig. 5</label><caption><p>Proposed diagnostic algorithm for ichthyosis with confetti. Medical history and physical examination raise diagnosis suspicion. Histological examination and keratin immunolocalization show specific findings, such as suprabasal keratinocyte vacuolization and nuclear keratin staining, respectively. Electron microscopy may further support the diagnosis. Finally, mutational analysis of <italic>KRT10/KRT1</italic> genes represents the gold standard to confirm the diagnosis. Findings relevant to differential diagnosis are in <italic>bold</italic>
</p></caption><graphic xlink:href="13023_2015_336_Fig5_HTML" id="MO5"/></fig></p></sec><sec id="Sec9"><title>Differential diagnosis</title><p>IWC at its onset is usually confused with the erythrodermic form of autosomal recessive congenital ichthyosis (ARCI), congenital ichthyosiform erythroderma (CIE) [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. The following clinical criteria should be used for the differential diagnosis of IWC: i. the evolution over time of skin manifestations, in particular a progressive worsening of the hyperkeratosis may be suggestive of IWC; ii. the type of scaling and hyperkeratosis, as severe, adherent hyperkeratotic plaques are not usually seen in CIE; iii. the presence of additional dermatologic features, in particular ear and mammillae hypoplasia, and hypertrichosis; iv. the family history which may point toward a particular mode of inheritance and, above all, v. the appearance of confetti-like spots which drives the correct diagnosis. Histopathological and immunopathological features also allow to differentiate IWC from CIE. Indeed, keratinocyte vacuolization and K10 reduced cytoplasmic labeling and nuclear staining are not found in CIE. Table&#160;<xref rid="Tab2" ref-type="table">2</xref> summarizes differences between CIE and IWC [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. IWC can also be differentiated from syndromic ichthyoses, in particular Netherton syndrome [<xref ref-type="bibr" rid="CR31">31</xref>] which manifests at birth with ichthyosiform erythroderma, but also presents specific hair alterations (i.e. trichorrhexis invaginata). The absence of overt skin blistering in infancy allows to distinguish IWC from other keratinopathic ichthyoses [<xref ref-type="bibr" rid="CR4">4</xref>].<table-wrap id="Tab2"><label>Table 2</label><caption><p>Differential diagnosis between congenital ichthyosiform erythroderma (CIE) and ichthyosis with confetti (IWC) / congenital reticular ichthyosiform erythroderma (CRIE)</p></caption><table-wrap-foot><p>
<sup>a</sup>
<italic>ABCA12</italic> ATP-binding cassette subfamily A12; <italic>ALOX</italic> arachidonate lipoxygenase; <italic>CERS3</italic> ceramide synthase 3; <italic>CYP4F22</italic> cytochrome P450 4&#160;F22; <italic>NIPAL4</italic> NIPA-like domain containing 4; <italic>PNPLA1</italic> patatin-like phospholipase domain-containing protein 1; <italic>TGM1</italic> transglutaminase-1; <italic>KRT10</italic>/<italic>KRT1</italic> keratin 10/1 [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec10"><title>Genetic counselling</title><p>Genetic counselling in IWC is usually required by the dermatologist who has in charge the affected patient/family. It is aimed to: i. confirm the diagnosis, ii. ascertain disease recurrence risk in future pregnancies, and iii. plan prenatal diagnosis. Histopathological and immunopathological analyses should be considered as first steps in the diagnostic pathway as they permit to put in evidence the peculiar tissue architecture and keratin nuclear staining of affected skin, thus allowing early diagnosis before revertant skin spots become evident [<xref ref-type="bibr" rid="CR17">17</xref>]. Then, molecular analysis of <italic>KRT10</italic> and, if IWC-II subtype is suspected, of <italic>KRT1</italic> gene is aimed at identifying the heterozygous frameshift mutation in the hotspot genomic region coding for the C-terminal tail of keratins 10 and 1. Mutation identification provides confirmation of the disease subtype and allows to support the autosomal dominant mode of inheritance, which has a 50&#160;% recurrence risk for subsequent pregnancies of affected individuals. Knowledge of the mutation also provides a tool to monitor recurrence risk by prenatal testing. However, IWC often manifests as a sporadic case, making difficult the diagnosis in infancy when &#8220;confetti like&#8221; spots are not yet evident and, thus, CIE is usually suspected. The latter is classically inherited as an autosomal recessive trait, which bears a 25&#160;% recurrence risk for subsequent pregnancies, while sporadic IWC has a lower risk of recurrence as it results from <italic>de novo</italic> event(s) during gametogenesis or at conception. Therefore, molecular analysis is the only way to properly counsel the couples in sporadic IWC. Molecular confirmation after diagnosis by immunofluorescence also provides a prenatal diagnostic tool in selected pregnancies to exclude gonadal mosaicism.</p></sec><sec id="Sec11"><title>Management including treatment</title><p>Due to the rarity of the disease, there are no controlled studies on IWC management. In general, care of the disease follows the rules for treatment of ARCI patients.</p><p>Like for other congenital ichthyosis forms, the management of IWC in the neonate, presenting either with ichthyosiform erythroderma or colloidon baby, requires admission to a neonatal intensive care unit and a multidisciplinary approach, with nursing staff, neonatologists, dermatologists and other specialists [<xref ref-type="bibr" rid="CR32">32</xref>]. In particular, the skin barrier function of the newborn is greatly compromised and ongoing water loss can lead to dehydration and electrolyte imbalance [<xref ref-type="bibr" rid="CR33">33</xref>]. Moreover defective barrier allows bacteria and yeast colonization, increasing risks of infection and sepsis [<xref ref-type="bibr" rid="CR17">17</xref>]. Thus, neonate care includes providing a temperature controlled environment via a humidified incubator, and frequent application of lubricants such as petrolatum-based products under sterile conditions [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. Urinary output, electrolytes and weight should be monitored and managed with intravenous hydration, electrolyte repletion and additional nutritional input when necessary. Close monitoring and prompt systemic treatment with antibiotics for infection is essential.</p><p>Therapy of infants, children and adults affected with ichthyosis, including IWC, is not curative but rather aimed at symptom relieving. Daily bathing with water and sodium bicarbonate alkalinizes the epidermis and is helpful for many patients, especially for mechanical scale removal. If sodium bicarbonate is not tolerated, rice starch can be used and is preferred in the first year of life. During bathing, gentle mechanical keratolysis can be obtained using sponges or microfiber cloths. Bland emollients such as petrolatum-based products should be applied several times a day, especially after bathing, to prevent drying. Starting from the second year of life, keratolysis may be obtained through alpha-hydroxy (e.g. lactic and glycolic) acids and urea or combination of these ingredients. Alpha-hydroxy acids-based lotions reduce corneocyte adhesion and skin thickness and relieve itching. Urea creams decrease dryness and scaling and improve skin permeability barrier function by regulating epidermal gene activity [<xref ref-type="bibr" rid="CR34">34</xref>]. Of note, topical urea and alpha-hydroxy acids can also cause skin irritation and should be applied with caution and only on stubborn areas in the first three years of life. Moreover, alpha-hydroxy acids and urea creams may cause systemic absorption with metabolic acidosis or elevating plasma urea levels, respectively, when applied over large body surfaces in infants and toddlers [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. The use of a topical retinoid, tazarotene cream, has been reported in a single IWC patient, specifically on skin areas presenting marked hyperkeratosis and around eyes to prevent ectropion [<xref ref-type="bibr" rid="CR18">18</xref>]. Although topical tazarotene is increasingly used in ichthyosis patients [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>], it can be irritating [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR39">39</xref>] and thus not tolerated in erythrodermic forms of the disease. Its use in IWC should be therefore cautiously considered for selected skin areas, such as hyperkeratotic ones or eyelids, and tolerance evaluated in each patient. Despite low systemic absorption [<xref ref-type="bibr" rid="CR40">40</xref>], rules for pregnancy avoidance during systemic retinoid treatments should also be applied to tazarotene topical therapy.</p><p>Due to disease severity, oral retinoids, at first etretinate [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR6">6</xref>] and then acitretin [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR17">17</xref>], have been used in most IWC patients with positive results, including extension of the areas of normal confetti-like skin [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. Systemic retinoids decrease cell proliferation, thus thinning the stratum corneum, normalize keratinocyte differentiation, facilitate desquamation through downregulation of desmosomal proteins, and have anti-inflammatory properties [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR42">42</xref>]. Of note, they have been also shown to downregulate K10 expression [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]. However, the lowest possible dose of a systemic retinoid producing desired clinical outcomes needs to be titrated. Few IWC patients require more than 0.5&#160;mg/kg of acitretin once a day [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. Importantly, in women of childbearing age pregnancy must be excluded by negative pregnancy test (serum levels of human chorionic gonadotropin) within 2&#160;weeks prior to therapy and effective contraception has to be initiated 4&#160;weeks before, during and for 3&#160;years after retinoid therapy [<xref ref-type="bibr" rid="CR44">44</xref>].</p><p>Acute adverse effects of systemic retinoids include skin irritation, fragility and tenderness, mucocutanous toxicities (in particular cheilitis, epistaxis, eye irritation), hair loss, and laboratory abnormalities in blood cell counts, transaminases and serum lipids [<xref ref-type="bibr" rid="CR44">44</xref>]. Complete blood count, liver function, cholesterol and lipid levels must be monitored.</p><p>Possible long-term retinoid complications include premature epiphyseal closure, hyperostosis and tendon calcifications [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. Although not reported to date in IWC, they represent an indication to limit the duration of retinoid therapy or to periodically interrupt their administration, e.g. during summertime. Baseline radiographs should also be obtained before programming long-term retinoid therapy. Frequency of X-ray follow-ups, complemented if required with bone density scan, will depend on baseline findings and on clinical manifestations and symptoms. In addition, it has been hypothesized that retinoids might interfere with vitamin D metabolism, as their vitamin A-like biologic activity may hinder vitamin D action [<xref ref-type="bibr" rid="CR45">45</xref>]. Of note, vitamin D deficiency has been described in most types of ichthyoses, in particular severe forms, and attributed to different factors, such as poor sunlight penetration due to hyperkeratotic skin and limited sun exposure for cosmetic reasons or sun-induced pain and pruritus [<xref ref-type="bibr" rid="CR46">46</xref>]. Therefore, it is currently recommended to screen all congenital ichthyoses for calcium, phosphorus and vitamin D3 levels and to provide supplementation if required, in order to treat vitamin D3 deficiency and prevent possible complications, such as osteoporosis and rickets. This recommendation should apply also to IWC, although no data on ions and vitamin D3 levels in these patients have been reported to date.</p><p>For infection control in IWC, topical antiseptics and antimicrobials must be combined with appropriate systemic therapy. Among other IWC complications, severe ectropion should be managed by an ophthalmologist to avoid desiccation, e.g. through regular application of liquid tears and eye lubricants, and plastic surgery may be required. Routine otolaryngologist visits are required to remove desquamated skin from ear canals. Contractures and gait abnormalities should be evaluated by a combined team of orthopedists, neurologists and plastic surgeons and physical therapy should be instituted for patients with these findings. Psychological support may be of benefit to both patients and their families. Regular examination for skin cancer risk is recommended in adulthood.</p></sec><sec id="Sec12"><title>Prognosis</title><p>IWC, as most other heritable ichthyoses, is a condition that requires significant attention in the neonatal period. Although at present there is no curative therapy for all forms of ichthyoses, including IWC, treatments have improved considerably over the years. Topical medications can reduce scaling and, thus, patient quality of life. In addition, retinoid therapies decrease scaling and hyperkeratosis, and may help in preventing and treating ectropion. Nevertheless, treatments remain symptomatic and topical ones are time-consuming, challenging patient and caregiver compliance. Therefore, personalized multidisciplinary care plans should be set up and regularly up-dated by combined dermatologist and patient efforts. In this context, the support of patient organizations (see Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1) will help affected individuals and their families to better cope with the disease.</p></sec><sec id="Sec13"><title>Unresolved questions</title><p>There have been recently major advances in our understanding of the genetic basis of IWC, with the identification of <italic>KRT10</italic> and <italic>KRT1</italic> mutations. However, several questions remain unanswered. First, although IWC is considered a nonsyndromic ichthyosis, it is also true that a spectrum of ectodermal malformations and neurological findings leading to different degrees of disability have been described in affected individuals without any apparent genotype-phenotype correlation. Indeed, among 40 previously reported IWC patients, 7 showed both ear deformities and mammillae hypoplasia [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR19">19</xref>], whereas 6 presented ear deformities [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR18">18</xref>] or mammillae hypoplasia [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR19">19</xref>] alone (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). Moreover, 4 out of 40 IWC cases were diagnosed with peripheral hyperreflexia [<xref ref-type="bibr" rid="CR15">15</xref>] (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). This led some Authors to suggest a reclassification of IWC as a syndromic ichthyosis [<xref ref-type="bibr" rid="CR19">19</xref>].</p><p>Mutations affecting K10/K1 heterodimers trigger keratinocyte hyperproliferation [<xref ref-type="bibr" rid="CR24">24</xref>], which explains acanthosis and hyperkeratosis in IWC patients. Although K10/K1 are not expressed in nail bed, they are detectable in all other regions of the nail unit, including eponychium, hyponychium and the apical matrix [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]. Therefore <italic>KRT10/KRT1</italic> mutations may also cause nail dystrophies in IWC patients. In contrast, K10/K1 are absent from the hair follicle, except for the infundibulum [<xref ref-type="bibr" rid="CR47">47</xref>], thus raising the question of pathogenetic mechanisms underlying hypertrichosis in IWC. Hypertrichosis is limited to areas of ichthyotic skin and Spoerri et al. hypothesized that it may be due to inflammation and hyperemia, as it happens in postcast hypertrichosis [<xref ref-type="bibr" rid="CR19">19</xref>].</p><p>Another open issue is the timing of mitotic recombination leading to the generation of revertant cells. Spots become evident as early as 2.5&#160;years of age [<xref ref-type="bibr" rid="CR17">17</xref>] and can reach a diameter of 4&#160;cm in adulthood [<xref ref-type="bibr" rid="CR13">13</xref>]. Since a white spot represents the expansion of a single homozygotic revertant daughter cell in the absence of phenotypic evidence of homozygotic mutant daughter cell [<xref ref-type="bibr" rid="CR13">13</xref>], the recombination event should involve the epidermal stem cell unit, the specification of which is thought to occur during embryogenesis [<xref ref-type="bibr" rid="CR49">49</xref>]. This leads to think that generation of revertant cells might begin already in fetal skin. Moreover, as mutant K10 is thought to be involved in triggering the recombination event, <italic>KRT10</italic> should be transcriptionally active in the epidermal stem cell. However, evidence of <italic>KRT10</italic> expression in epidermal stem cells is still quite limited [<xref ref-type="bibr" rid="CR50">50</xref>].</p><p>A further intriguing question concerns the extremely high rate of mitotic recombination. As different types of keratin mutations lead to keratinization diseases without revertant mosaicism, this implicates the C-terminal frameshift peptide of mutant K10 and K1, and its nuclear localization in the elevated rate of reversion in IWC [<xref ref-type="bibr" rid="CR15">15</xref>]. Interestingly, revertant spots associated with IWC-II are lesser in number and smaller in size compared to classic IWC and harbor clinically apparent affected skin islands [<xref ref-type="bibr" rid="CR16">16</xref>]. Moreover, spot-derived keratinocytes of IWC-II give rise to mixed cultures of revertant and mutant cells, thus revertant cells seem to have a lesser growth selective advantage [<xref ref-type="bibr" rid="CR16">16</xref>]. Finally, nuclear K1 staining is clearly evident in epithelial cells transfected with mutant K1, but not in IWC-II patient epidermis [<xref ref-type="bibr" rid="CR16">16</xref>]. The explanation for these observations might be dual: i. the sequence of the mutant C-terminal frame-shifted K1 peptide harbors very few positive-charged residues compared to mutant K10 and ii. only the K10 protein has been linked to cell cycle control [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR52">52</xref>], suggesting that mutant K10 might gain and/or loss an activity that interferes with this process. However, the relationship between IWC <italic>KRT10/KRT1</italic> mutations and the frequency of mitotic recombination events leading to revertant cells remains to be determined.</p><p>Adult individuals with IWC may also have a higher risk to develop NMSCs [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. Although such risk should be carefully re-evaluated by long term patient follow-up, tumour susceptibility in IWC may have a genetic rationale related to the mechanism of somatic mosaicism. Indeed, LOH occurring on chromosome 17q not only involves the <italic>KRT10</italic> locus but can also reduce to homozygosity mutations and/or variants in epithelial cancer susceptibility loci distal to the <italic>KRT10</italic> allele. For example, within chromosomal band 17q21.31 several of these loci have been mapped, including the <italic>BRCA1</italic> tumor suppressor [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR54">54</xref>]. Homozygotic revertant cells might have a selective growth advantage also as a consequence of LOH events in tumor suppressor loci. However, available data on <italic>BRCA1</italic> mutations and non-melanoma skin cancer show non-significant association [<xref ref-type="bibr" rid="CR54">54</xref>]. In addition, it is not known whether squamous cell carcinomas reported in IWC individuals developed from revertant or erythrokeratotic skin. Finally, NMSCs have been reported also in other ichthyoses, in particular erythrodermic ones, which do not present revertant mosaicism [<xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR56">56</xref>].</p></sec><sec id="Sec14"><title>Future perspectives</title><p>Revertant skin spots could be exploited in future as a cell source for a &#8220;natural gene therapy&#8221; approach in IWC. The feasibility of <italic>ex-vivo</italic> gene therapy for genetic skin disorders has been demonstrated by the successful engraftment of <italic>LAMB3</italic> cDNA retrovirally-corrected epidermal sheets and maintenance of a functional epidermis in a 36-year old male with non-Herlitz junctional EB [<xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR58">58</xref>]. However, concerns remain regarding the safety of this approach as there is an oncogenic potential related to random insertion of retroviral vectors [<xref ref-type="bibr" rid="CR59">59</xref>]. By contrast, the natural occurrence of revertant mosaicism creates a unique opportunity for therapy in patients, because the presence of reverted cells circumvents the need for viral vectors. Persistent ulcers in a patient with non-Herlitz junctional EB, caused by mutations in the <italic>LAMB3</italic> gene, have been recently treated by transplantation of punch biopsy specimens taken from one of his revertant patches with complete re-epithelialization and restoration of a healthy phenotype and genotype in the grafted areas [<xref ref-type="bibr" rid="CR60">60</xref>]. Stable reversion of the EB phenotype by transplantation of revertant skin in this patient may be a pioneering work for the development of the &#8220;revertant cell therapy&#8221; for other genetic diseases with somatic revertant mosaicism, such as IWC. To date, the only attempt to utilize revertant cell therapy in a clinical setting was performed in an individual with non-Herlitz junctional EB associated with mutations in <italic>COL17A1</italic> who presented revertant skin patches [<xref ref-type="bibr" rid="CR61">61</xref>]. In this case, revertant keratinocytes were isolated and expanded into epidermal sheets that were subsequently grafted back onto the patient. However fewer than 3&#160;% of the cells remained corrected in the graft and there was no clinically relevant outcome.</p><p>The persistence of revertant clones in patients with revertant mosaicism indicates that reversion events occur in epidermal stem cells and that naturally-corrected stem cell clones may be under strong positive selection [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR62">62</xref>]. Therefore, efficacy and long-term persistence of the regenerated epidermis after autotransplantation requires epidermal stem cell maintenance in cultured sheets and their grafting onto the patients [<xref ref-type="bibr" rid="CR63">63</xref>]. We hypothesize that, with optimized culture conditions, the &#8220;revertant cell therapy&#8221; might be applied in future to IWC. Nevertheless, in this scenario, the possibility of homozygosity for mutations in tumor suppressors should be carefully considered together with the potential therapeutic advantage of reversion.</p></sec></sec><sec id="Sec15" sec-type="conclusions"><title>Conclusions</title><p>IWC is a very rare genodermatosis and represents the most impressive example of revertant somatic mosaicism. The IWC phenotype is characterized by a wide spectrum of clinical features, in addition to erythrodermic ichthyosis. The recent discoveries in IWC genetics have led to a better understanding of disease aetiology and made available molecular diagnostic tools. Disease care requires a multidisciplinary approach, but remains symptomatic. However, based on current scientific and technological progresses, new therapeutic strategies potentially able to cure skin manifestations might be developed in future.</p><sec id="Sec16"><title>Consent</title><p>Written informed consent for patient reexamination for the present review and for patient data and image publication was obtained from patients&#8217; parents.</p></sec></sec></body><back><app-group><app id="App1"><sec id="Sec17"><title>Additional file</title><p><media position="anchor" xlink:href="13023_2015_336_MOESM1_ESM.doc" id="MOESM1"><label>Additional file 1: Table S1.</label><caption><p>Worldwide ichthyosis foundations and patient organizations. (DOC 31 kb)</p></caption></media></p></sec></app></app-group><glossary><title>Abbreviations</title><def-list><def-item><term>IWC</term><def><p>Ichthyosis with confetti</p></def></def-item><def-item><term>CRIE</term><def><p>Congenital reticular ichthyosiform erythroderma</p></def></def-item><def-item><term>CIE</term><def><p>Congenital ichthyosiform erythroderma</p></def></def-item><def-item><term>MAUIE</term><def><p>Micropinnae, alopecia universalis, congenital ichthyosis and ectropion</p></def></def-item><def-item><term>PPK</term><def><p>Palmoplantar keratoderma</p></def></def-item><def-item><term>NMSC</term><def><p>Non-melanoma skin cancer</p></def></def-item><def-item><term>K/<italic>KRT</italic></term><def><p>Keratin (protein/<italic>gene</italic>)</p></def></def-item><def-item><term>IF</term><def><p>Intermediate filaments</p></def></def-item><def-item><term>LOH</term><def><p>Loss of heterozygosity</p></def></def-item><def-item><term>ARCI</term><def><p>Autosomal recessive congenital ichthyosis</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Competing interests</bold></p><p>The authors declare that they have competing interests.</p></fn><fn><p><bold>Authors&#8217; contributions</bold></p><p>LG performed the literature search and wrote the manuscript. DC participated in writing and reviewing the &#8220;aetiology&#8221;, &#8220;genetic counseling&#8221; and &#8220;unresolved questions&#8221; sections and provided molecular expertise. AD and MEH contributed to the clinical, diagnostic and therapeutic sections. GZ provided clinical and immunopathological advice, and supervised and critically revised the entire manuscript. The figures are from Istituto Dermopatico dell&#8217;Immacolata and Bambino Ges&#249; Children's Hospital. All authors read and approved the final manuscript.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We thank patient families for contributing to and supporting our study. Authors also acknowledge the Italian Ministry of Health (Ricerca Corrente Program) and Association Athina Ichtyose Monaco for the support.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camenzind</surname><given-names>M</given-names></name><name><surname>Harms</surname><given-names>M</given-names></name><name><surname>Chavaz</surname><given-names>P</given-names></name><name><surname>Saurat</surname><given-names>JH</given-names></name></person-group><article-title>Confetti ichthyosis</article-title><source>Ann Dermatol Venereol.</source><year>1984</year><volume>111</volume><fpage>675</fpage><lpage>676</lpage><?supplied-pmid 6529087?><pub-id pub-id-type="pmid">6529087</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Happle</surname><given-names>R</given-names></name><name><surname>K&#252;ster</surname><given-names>W</given-names></name></person-group><article-title>Ichthyosis variegata: a new name for a neglected disease</article-title><source>J Am Acad Dermatol.</source><year>1997</year><volume>36</volume><fpage>500</fpage><pub-id pub-id-type="doi">10.1016/S0190-9622(97)80246-0</pub-id><?supplied-pmid 9091497?><pub-id pub-id-type="pmid">9091497</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marghescu</surname><given-names>S</given-names></name><name><surname>Anton-Lamprecht</surname><given-names>I</given-names></name><name><surname>Rudolph</surname><given-names>PO</given-names></name><name><surname>Kaste</surname><given-names>R</given-names></name></person-group><article-title>Congenital reticular ichthyosiform erythroderma</article-title><source>Hautarzt</source><year>1984</year><volume>35</volume><fpage>522</fpage><lpage>529</lpage><?supplied-pmid 6500934?><pub-id pub-id-type="pmid">6500934</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oji</surname><given-names>V</given-names></name><name><surname>Tadini</surname><given-names>G</given-names></name><name><surname>Akiyama</surname><given-names>M</given-names></name><name><surname>Blanchet Bardon</surname><given-names>C</given-names></name><name><surname>Bodemer</surname><given-names>C</given-names></name><name><surname>Bourrat</surname><given-names>E</given-names></name><etal/></person-group><article-title>Revised nomenclature and classification of inherited ichthyoses: results of the First Ichthyosis Consensus Conference in Sor&#232;ze 2009</article-title><source>J Am Acad Dermatol.</source><year>2010</year><volume>63</volume><fpage>607</fpage><lpage>641</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2009.11.020</pub-id><?supplied-pmid 20643494?><pub-id pub-id-type="pmid">20643494</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rufli</surname><given-names>T</given-names></name><name><surname>Schneider</surname><given-names>BV</given-names></name><name><surname>Schnyder</surname><given-names>UW</given-names></name></person-group><article-title>Non-bullous erythroderma (congenital) ichthyosiforme with perinuclear shells</article-title><source>Hautarzt</source><year>1990</year><volume>41</volume><fpage>442</fpage><lpage>447</lpage><?supplied-pmid 2272828?><pub-id pub-id-type="pmid">2272828</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brusasco</surname><given-names>A</given-names></name><name><surname>Tadini</surname><given-names>G</given-names></name><name><surname>Cambiaghi</surname><given-names>S</given-names></name><name><surname>Ermacora</surname><given-names>E</given-names></name><name><surname>Grimalt</surname><given-names>R</given-names></name><name><surname>Caputo</surname><given-names>R</given-names></name></person-group><article-title>A case of congenital reticular ichthyosiform erythroderma-ichthyosis &#8216;en confettis&#8217;.</article-title><source>Dermatology</source><year>1994</year><volume>188</volume><fpage>40</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1159/000247084</pub-id><?supplied-pmid 8305756?><pub-id pub-id-type="pmid">8305756</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elbaum</surname><given-names>DJ</given-names></name><name><surname>Kurz</surname><given-names>G</given-names></name><name><surname>MacDuff</surname><given-names>M</given-names></name></person-group><article-title>Increased incidence of cutaneous carcinomas in patients with congenital ichthyosis</article-title><source>J Am Acad Dermatol</source><year>1995</year><volume>33</volume><fpage>884</fpage><lpage>886</lpage><pub-id pub-id-type="doi">10.1016/0190-9622(95)90428-X</pub-id><?supplied-pmid 7593802?><pub-id pub-id-type="pmid">7593802</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hendrix</surname><given-names>JD</given-names><suffix>Jr</suffix></name><name><surname>Patterson</surname><given-names>JW</given-names></name><name><surname>Greer</surname><given-names>KE</given-names></name></person-group><article-title>Skin cancer associated with ichthyosis: the MAUIE syndrome</article-title><source>J Am Acad Dermatol.</source><year>1997</year><volume>37</volume><fpage>1000</fpage><lpage>1002</lpage><pub-id pub-id-type="doi">10.1016/S0190-9622(97)70084-7</pub-id><?supplied-pmid 9418775?><pub-id pub-id-type="pmid">9418775</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brusasco</surname><given-names>A</given-names></name><name><surname>Cambiaghi</surname><given-names>S</given-names></name><name><surname>Tadini</surname><given-names>G</given-names></name><name><surname>Berti</surname><given-names>E</given-names></name><name><surname>Caputo</surname><given-names>R</given-names></name></person-group><article-title>Unusual hyperpigmentation developing in congenital reticular ichthyosiform erythroderma (ichthyosis variegata)</article-title><source>Br J Dermatol.</source><year>1998</year><volume>139</volume><fpage>893</fpage><lpage>896</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2133.1998.02521.x</pub-id><?supplied-pmid 9892962?><pub-id pub-id-type="pmid">9892962</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Metze</surname><given-names>D</given-names></name><name><surname>Raghunath</surname><given-names>M</given-names></name><name><surname>Traupe</surname><given-names>H</given-names></name></person-group><article-title>Congenital reticular ichthyosiform erythroderma: a histologic, immunohistochemical and ultrastructural study of a rare keratinization disorder</article-title><source>J Invest Dermatol.</source><year>2000</year><volume>115</volume><fpage>923</fpage></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torrelo</surname><given-names>A</given-names></name><name><surname>Marrero</surname><given-names>MD</given-names></name><name><surname>Mediero</surname><given-names>IG</given-names></name><name><surname>Mart&#237;nez</surname><given-names>MA</given-names></name><name><surname>Zambrano</surname><given-names>A</given-names></name></person-group><article-title>Progressive macular leucoderma in a patient with congenital ichthyosiform erythroderma</article-title><source>Br J Dermatol.</source><year>2001</year><volume>144</volume><fpage>1280</fpage><lpage>1282</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2133.2001.04259.x</pub-id><?supplied-pmid 11422068?><pub-id pub-id-type="pmid">11422068</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krunic</surname><given-names>AL</given-names></name><name><surname>Palcesky</surname><given-names>D</given-names></name><name><surname>Busbey</surname><given-names>S</given-names></name><name><surname>Medenica</surname><given-names>M</given-names></name></person-group><article-title>Congenital reticular ichthyosiform erythroderma-ichthyosis variegata: a case report and review of the literature</article-title><source>Acta Derm Venereol.</source><year>2003</year><volume>83</volume><fpage>36</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1080/00015550310002684</pub-id><?supplied-pmid 12636020?><pub-id pub-id-type="pmid">12636020</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">Choate KA, Lu Y, Zhou J, Choi M, Elias PM, Farhi A, et al. Mitotic recombination in patients with ichthyosis causes reversion of dominant mutations in <italic>KRT10</italic>. Science. 2010;330:94&#8211;7.</mixed-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other">Burger B, Spoerri I, Schubert M, Has C, Itin PH. Description of the natural course and clinical manifestations of ichthyosis with confetti caused by a novel <italic>KRT10</italic> mutation. Br J Dermatol. 2012;166:434&#8211;9.</mixed-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choate</surname><given-names>KA</given-names></name><name><surname>Milstone</surname><given-names>LM</given-names></name></person-group><article-title>Phenotypic expansion in ichthyosis with confetti</article-title><source>JAMA Dermatol.</source><year>2015</year><volume>151</volume><fpage>15</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1001/jamadermatol.2014.2525</pub-id><?supplied-pmid 25210951?><pub-id pub-id-type="pmid">25210951</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="other">Choate KA, Lu Y, Zhou J, Elias PM, Zaidi S, Paller AS, et al. Frequent somatic reversion of <italic>KRT1</italic> mutations in ichthyosis with confetti. J Clin Invest. 2015;125:1703&#8211;7.</mixed-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diociaiuti</surname><given-names>A</given-names></name><name><surname>Fortugno</surname><given-names>P</given-names></name><name><surname>El Hachem</surname><given-names>M</given-names></name><name><surname>Angelo</surname><given-names>C</given-names></name><name><surname>Proto</surname><given-names>V</given-names></name><name><surname>De Luca</surname><given-names>N</given-names></name><etal/></person-group><article-title>Early immunopathological diagnosis of ichthyosis with confetti in two sporadic cases with new mutations in keratin 10</article-title><source>Acta Derm Venereol.</source><year>2014</year><volume>94</volume><fpage>579</fpage><lpage>582</lpage><pub-id pub-id-type="doi">10.2340/00015555-1796</pub-id><?supplied-pmid 24626314?><pub-id pub-id-type="pmid">24626314</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="other">Long MC. Ichthyosis with confetti: a rare diagnosis and treatment plan. BMJ Case Rep. 2014. doi:10.1136/bcr-2014-204509.</mixed-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">Spoerri I, Brena M, De Mesmaeker J, Schlipf N, Fischer J, Tadini G, et al. The phenotypic and genotypic spectra of ichthyosis with confetti plus novel genetic variation in the 3' end of <italic>KRT10</italic>: from disease to a syndrome. JAMA Dermatol. 2015;151:64&#8211;9.</mixed-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="other">Orphanet. The portal for rare diseases and orphan drugs. <ext-link ext-link-type="uri" xlink:href="http://www.orpha.net/consor/cgi-bin/index.php">http://www.orpha.net/consor/cgi-bin/index.php</ext-link>. Accessed on April 4, 2015.</mixed-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moll</surname><given-names>R</given-names></name><name><surname>Divo</surname><given-names>M</given-names></name><name><surname>Langbein</surname><given-names>L</given-names></name></person-group><article-title>The human keratins: biology and pathology</article-title><source>Histochem Cell Biol.</source><year>2008</year><volume>129</volume><fpage>705</fpage><lpage>733</lpage><pub-id pub-id-type="doi">10.1007/s00418-008-0435-6</pub-id><?supplied-pmid 18461349?><pub-id pub-id-type="pmid">18461349</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chamcheu</surname><given-names>JC</given-names></name><name><surname>Siddiqui</surname><given-names>IA</given-names></name><name><surname>Syed</surname><given-names>DN</given-names></name><name><surname>Adhami</surname><given-names>VM</given-names></name><name><surname>Liovic</surname><given-names>M</given-names></name><name><surname>Mukhtar</surname><given-names>H</given-names></name></person-group><article-title>Keratin gene mutations in disorders of human skin and its appendages</article-title><source>Arch Biochem Biophys.</source><year>2011</year><volume>508</volume><fpage>123</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1016/j.abb.2010.12.019</pub-id><?supplied-pmid 21176769?><pub-id pub-id-type="pmid">21176769</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haines</surname><given-names>RL</given-names></name><name><surname>Lane</surname><given-names>EB</given-names></name></person-group><article-title>Keratins and disease at a glance</article-title><source>J Cell Sci.</source><year>2012</year><volume>125</volume><fpage>3923</fpage><lpage>3928</lpage><pub-id pub-id-type="doi">10.1242/jcs.099655</pub-id><?supplied-pmid 23104737?><pub-id pub-id-type="pmid">23104737</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>X</given-names></name><name><surname>Hobbs</surname><given-names>RP</given-names></name><name><surname>Coulombe</surname><given-names>PA</given-names></name></person-group><article-title>The expanding significance of keratin intermediate filaments in normal and diseased epithelia</article-title><source>Curr Opin Cell Biol.</source><year>2013</year><volume>25</volume><fpage>47</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1016/j.ceb.2012.10.018</pub-id><?supplied-pmid 23270662?><pub-id pub-id-type="pmid">23270662</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McLean</surname><given-names>WH</given-names></name><name><surname>Irvine</surname><given-names>AD</given-names></name></person-group><article-title>Disorders of keratinisation: from rare to common genetic diseases of skin and other epithelial tissues</article-title><source>Ulster Med J.</source><year>2007</year><volume>76</volume><fpage>72</fpage><lpage>82</lpage><?supplied-pmid 17476820?><pub-id pub-id-type="pmid">17476820</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toivola</surname><given-names>DM</given-names></name><name><surname>Boor</surname><given-names>P</given-names></name><name><surname>Alam</surname><given-names>C</given-names></name><name><surname>Strnad</surname><given-names>P</given-names></name></person-group><article-title>Keratins in health and disease</article-title><source>Curr Opin Cell Biol.</source><year>2015</year><volume>32</volume><fpage>73</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1016/j.ceb.2014.12.008</pub-id><?supplied-pmid 25599598?><pub-id pub-id-type="pmid">25599598</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korge</surname><given-names>BP</given-names></name><name><surname>Gan</surname><given-names>SQ</given-names></name><name><surname>McBride</surname><given-names>OW</given-names></name><name><surname>Mischke</surname><given-names>D</given-names></name><name><surname>Steinert</surname><given-names>PM</given-names></name></person-group><article-title>Extensive size polymorphism of the human keratin 10 chain resides in the C-terminal V2 subdomain due to variable numbers and sizes of glycine loops</article-title><source>Proc Natl Acad Sci U S A.</source><year>1992</year><volume>89</volume><fpage>910</fpage><lpage>914</lpage><pub-id pub-id-type="doi">10.1073/pnas.89.3.910</pub-id><?supplied-pmid 1371013?><pub-id pub-id-type="pmid">1371013</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Traupe</surname><given-names>H</given-names></name><name><surname>Fischer</surname><given-names>J</given-names></name><name><surname>Oji</surname><given-names>V</given-names></name></person-group><article-title>Nonsyndromic types of ichthyoses - an update</article-title><source>J Dtsch Dermatol Ges.</source><year>2014</year><volume>12</volume><fpage>109</fpage><lpage>121</lpage><?supplied-pmid 24119255?><pub-id pub-id-type="pmid">24119255</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><mixed-citation publication-type="other">Grall A, Guaguere E, Planchais S, Grond S, Bourrat E, Hausser I, et al. <italic>PNPLA1</italic> mutations cause autosomal recessive congenital ichthyosis in golden retriever dogs and humans. Nat Genet. 2012;44:140&#8211;7.</mixed-citation></ref><ref id="CR30"><label>30.</label><mixed-citation publication-type="other">Radner FP, Marrakchi S, Kirchmeier P, Kim GJ, Ribierre F, Kamoun B, et al. Mutations in <italic>CERS3</italic> cause autosomal recessive congenital ichthyosis in humans. PLoS Genet. 2013;9:e1003536.</mixed-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hovnanian</surname><given-names>A</given-names></name></person-group><article-title>Netherton syndrome: skin inflammation and allergy by loss of protease inhibition</article-title><source>Cell Tissue Res.</source><year>2013</year><volume>351</volume><fpage>289</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1007/s00441-013-1558-1</pub-id><?supplied-pmid 23344365?><pub-id pub-id-type="pmid">23344365</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Craiglow</surname><given-names>BG</given-names></name></person-group><article-title>Ichthyosis in the newborn</article-title><source>Semin Perinatol.</source><year>2013</year><volume>37</volume><fpage>26</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1053/j.semperi.2012.11.001</pub-id><?supplied-pmid 23419760?><pub-id pub-id-type="pmid">23419760</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dyer</surname><given-names>JA</given-names></name><name><surname>Spraker</surname><given-names>M</given-names></name><name><surname>Williams</surname><given-names>M</given-names></name></person-group><article-title>Care of the newborn with ichthyosis</article-title><source>Dermatol Ther.</source><year>2013</year><volume>26</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1111/j.1529-8019.2012.01555.x</pub-id><?supplied-pmid 23384016?><pub-id pub-id-type="pmid">23384016</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grether-Beck</surname><given-names>S</given-names></name><name><surname>Felsner</surname><given-names>I</given-names></name><name><surname>Brenden</surname><given-names>H</given-names></name><name><surname>Kohne</surname><given-names>Z</given-names></name><name><surname>Majora</surname><given-names>M</given-names></name><name><surname>Marini</surname><given-names>A</given-names></name><etal/></person-group><article-title>Urea uptake enhances barrier function and antimicrobial defense in humans by regulating epidermal gene expression</article-title><source>J Invest Dermatol.</source><year>2012</year><volume>132</volume><fpage>1561</fpage><lpage>1572</lpage><pub-id pub-id-type="doi">10.1038/jid.2012.42</pub-id><?supplied-pmid 22418868?><pub-id pub-id-type="pmid">22418868</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oji</surname><given-names>V</given-names></name><name><surname>Traupe</surname><given-names>H</given-names></name></person-group><article-title>Ichthyosis: clinical manifestations and practical treatment options</article-title><source>Am J Clin Dermatol.</source><year>2009</year><volume>10</volume><fpage>351</fpage><lpage>364</lpage><pub-id pub-id-type="doi">10.2165/11311070-000000000-00000</pub-id><?supplied-pmid 19824737?><pub-id pub-id-type="pmid">19824737</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodr&#237;guez-Pazos</surname><given-names>L</given-names></name><name><surname>Ginarte</surname><given-names>M</given-names></name><name><surname>Vega</surname><given-names>A</given-names></name><name><surname>Toribio</surname><given-names>J</given-names></name></person-group><article-title>Autosomal recessive congenital ichthyosis</article-title><source>Actas Dermosifiliogr.</source><year>2013</year><volume>104</volume><fpage>270</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1016/j.ad.2011.11.015</pub-id><?supplied-pmid 23562412?><pub-id pub-id-type="pmid">23562412</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hofmann</surname><given-names>B</given-names></name><name><surname>Stege</surname><given-names>H</given-names></name><name><surname>Ruzicka</surname><given-names>T</given-names></name><name><surname>Lehmann</surname><given-names>P</given-names></name></person-group><article-title>Effect of topical tazarotene in the treatment of congenital ichthyoses</article-title><source>Br J Dermatol.</source><year>1999</year><volume>141</volume><fpage>642</fpage><lpage>646</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2133.1999.03101.x</pub-id><?supplied-pmid 10583110?><pub-id pub-id-type="pmid">10583110</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Craiglow</surname><given-names>BG</given-names></name><name><surname>Choate</surname><given-names>KA</given-names></name><name><surname>Milstone</surname><given-names>LM</given-names></name></person-group><article-title>Topical tazarotene for the treatment of ectropion in ichthyosis</article-title><source>JAMA Dermatol.</source><year>2013</year><volume>149</volume><fpage>598</fpage><lpage>600</lpage><pub-id pub-id-type="doi">10.1001/jamadermatol.2013.239</pub-id><?supplied-pmid 23677086?><pub-id pub-id-type="pmid">23677086</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stege</surname><given-names>H</given-names></name><name><surname>Hofmann</surname><given-names>B</given-names></name><name><surname>Ruzicka</surname><given-names>T</given-names></name><name><surname>Lehmann</surname><given-names>P</given-names></name></person-group><article-title>Topical application of tazarotene in the treatment of nonerythrodermic lamellar ichthyosis</article-title><source>Arch Dermatol.</source><year>1998</year><volume>134</volume><fpage>640</fpage><pub-id pub-id-type="doi">10.1001/archderm.134.5.640</pub-id><?supplied-pmid 9606345?><pub-id pub-id-type="pmid">9606345</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>V</given-names></name><name><surname>Cunningham</surname><given-names>BB</given-names></name><name><surname>Eichenfield</surname><given-names>LF</given-names></name><name><surname>Ali&#243;</surname><given-names>AB</given-names></name><name><surname>Buka</surname><given-names>RL</given-names></name></person-group><article-title>Treatment of ichthyosiform diseases with topically applied tazarotene: risk of systemic absorption</article-title><source>J Am Acad Dermatol</source><year>2007</year><volume>57</volume><issue>5 Suppl</issue><fpage>S123</fpage><lpage>S125</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2006.05.028</pub-id><?supplied-pmid 17938025?><pub-id pub-id-type="pmid">17938025</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torma</surname><given-names>H</given-names></name></person-group><article-title>Regulation of keratin expression by retinoids</article-title><source>Dermatoendocrinol.</source><year>2011</year><volume>3</volume><fpage>136</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.4161/derm.15026</pub-id><?supplied-pmid 22110773?><pub-id pub-id-type="pmid">22110773</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Digiovanna</surname><given-names>JJ</given-names></name><name><surname>Mauro</surname><given-names>T</given-names></name><name><surname>Milstone</surname><given-names>LM</given-names></name><name><surname>Schmuth</surname><given-names>M</given-names></name><name><surname>Toro</surname><given-names>JR</given-names></name></person-group><article-title>Systemic retinoids in the management of ichthyoses and related skin types</article-title><source>Dermatol Ther.</source><year>2013</year><volume>26</volume><fpage>26</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1111/j.1529-8019.2012.01527.x</pub-id><?supplied-pmid 23384018?><pub-id pub-id-type="pmid">23384018</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><mixed-citation publication-type="other">Li H, Torma H. Retinoids reduce formation of keratin aggregates in heat-stressed immortalized keratinocytes from an epidermolytic ichthyosis patient with a <italic>KRT10</italic> mutation. Acta Derm Venereol. 2013;93:44&#8211;9.</mixed-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ormerod</surname><given-names>AD</given-names></name><name><surname>Campalani</surname><given-names>E</given-names></name><name><surname>Goodfield</surname><given-names>MJ</given-names></name></person-group><article-title>BAD Clinical Standards Unit. British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology</article-title><source>Br J Dermatol</source><year>2010</year><volume>162</volume><fpage>952</fpage><lpage>963</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2133.2010.09755.x</pub-id><?supplied-pmid 20423353?><pub-id pub-id-type="pmid">20423353</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><mixed-citation publication-type="other">Neema S, Mukherjee S, Vasudevan B, Verma R, Moorchung N, Chatterjee M. Vitamin D deficiency after oral retinoid therapy for ichthyosis. Pediatr Dermatol. 2015. doi: 10.1111/pde.12614.</mixed-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frascari</surname><given-names>F</given-names></name><name><surname>Dreyfus</surname><given-names>I</given-names></name><name><surname>Rodriguez</surname><given-names>L</given-names></name><name><surname>Gennero</surname><given-names>I</given-names></name><name><surname>Ezzedine</surname><given-names>K</given-names></name><name><surname>Salles</surname><given-names>JP</given-names></name><etal/></person-group><article-title>Prevalence and risk factors of vitamin D deficiency in inherited ichthyosis: a French prospective observational study performed in a reference center</article-title><source>Orphanet J Rare Dis.</source><year>2014</year><volume>9</volume><fpage>127</fpage><pub-id pub-id-type="doi">10.1186/s13023-014-0127-3</pub-id><?supplied-pmid 25091406?><pub-id pub-id-type="pmid">25091406</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perrin</surname><given-names>C</given-names></name><name><surname>Langbein</surname><given-names>L</given-names></name><name><surname>Schweizer</surname><given-names>J</given-names></name></person-group><article-title>Expression of hair keratins in the adult nail unit: an immunohistochemical analysis of the onychogenesis in the proximal nail fold, matrix and nail bed</article-title><source>Br J Dermatol.</source><year>2004</year><volume>151</volume><fpage>362</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2133.2004.06108.x</pub-id><?supplied-pmid 15327543?><pub-id pub-id-type="pmid">15327543</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fleckman</surname><given-names>P</given-names></name><name><surname>Jaeger</surname><given-names>K</given-names></name><name><surname>Silva</surname><given-names>KA</given-names></name><name><surname>Sundberg</surname><given-names>JP</given-names></name></person-group><article-title>Comparative anatomy of mouse and human nail units</article-title><source>Anat Rec (Hoboken)</source><year>2013</year><volume>296</volume><fpage>521</fpage><lpage>532</lpage><pub-id pub-id-type="doi">10.1002/ar.22660</pub-id><pub-id pub-id-type="pmid">23408541</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strachan</surname><given-names>LR</given-names></name><name><surname>Ghadially</surname><given-names>R</given-names></name></person-group><article-title>Tiers of clonal organization in the epidermis: the epidermal proliferation unit revisited</article-title><source>Stem Cell Rev</source><year>2008</year><volume>4</volume><fpage>149</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1007/s12015-008-9020-6</pub-id><?supplied-pmid 18574734?><pub-id pub-id-type="pmid">18574734</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>UB</given-names></name><name><surname>Lowell</surname><given-names>S</given-names></name><name><surname>Watt</surname><given-names>FM</given-names></name></person-group><article-title>The spatial relationship between stem cells and their progeny in the basal layer of human epidermis: a new view based on whole-mount labelling and lineage analysis</article-title><source>Development.</source><year>1999</year><volume>126</volume><fpage>2409</fpage><lpage>2418</lpage><?supplied-pmid 10226000?><pub-id pub-id-type="pmid">10226000</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paramio</surname><given-names>JM</given-names></name><name><surname>Segrelles</surname><given-names>C</given-names></name><name><surname>Ruiz</surname><given-names>S</given-names></name><name><surname>Jorcano</surname><given-names>JL</given-names></name></person-group><article-title>Inhibition of protein kinase B (PKB) and PKC zeta mediates keratin K10-induced cell cycle arrest</article-title><source>Mol. Cell Biol.</source><year>2001</year><volume>21</volume><fpage>7449</fpage><lpage>7459</lpage><pub-id pub-id-type="doi">10.1128/MCB.21.21.7449-7459.2001</pub-id><?supplied-pmid 11585925?><pub-id pub-id-type="pmid">11585925</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>X</given-names></name><name><surname>Merched-Sauvage</surname><given-names>M</given-names></name><name><surname>Caulin</surname><given-names>C</given-names></name><name><surname>Roop</surname><given-names>DR</given-names></name><name><surname>Koch</surname><given-names>PJ</given-names></name></person-group><article-title>An unexpected role for keratin 10 end domains in susceptibility to skin cancer</article-title><source>J Cell Sci.</source><year>2006</year><volume>119</volume><fpage>5067</fpage><lpage>5076</lpage><pub-id pub-id-type="doi">10.1242/jcs.03298</pub-id><?supplied-pmid 17118961?><pub-id pub-id-type="pmid">17118961</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Permuth-Wey</surname><given-names>J</given-names></name><name><surname>Lawrenson</surname><given-names>K</given-names></name><name><surname>Shen</surname><given-names>HC</given-names></name><name><surname>Velkova</surname><given-names>A</given-names></name><name><surname>Tyrer</surname><given-names>JP</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31</article-title><source>Nat Commun</source><year>2013</year><volume>4</volume><fpage>1627</fpage><pub-id pub-id-type="doi">10.1038/ncomms2613</pub-id><?supplied-pmid 23535648?><pub-id pub-id-type="pmid">23535648</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><mixed-citation publication-type="other">Gumaste PV, Penn LA, Cymerman RM, Kirchhoff T, Polsky D, McLellan B. Skin cancer risk in <italic>BRCA1/2</italic> mutation carriers. Br J Dermatol. 2015;172:1498&#8211;506.</mixed-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Natsuga</surname><given-names>K</given-names></name><name><surname>Akiyama</surname><given-names>M</given-names></name><name><surname>Shimizu</surname><given-names>H</given-names></name></person-group><article-title>Malignant skin tumours in patients with inherited ichthyosis</article-title><source>Br J Dermatol</source><year>2011</year><volume>165</volume><fpage>263</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2133.2011.10381.x</pub-id><?supplied-pmid 21517795?><pub-id pub-id-type="pmid">21517795</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guerra</surname><given-names>L</given-names></name><name><surname>Fortugno</surname><given-names>P</given-names></name><name><surname>Sinistro</surname><given-names>A</given-names></name><name><surname>Proto</surname><given-names>V</given-names></name><name><surname>Zambruno</surname><given-names>G</given-names></name><name><surname>Didona</surname><given-names>B</given-names></name><etal/></person-group><article-title>Betapapillomavirus in multiple non-melanoma skin cancers of Netherton syndrome: Case report and published work review</article-title><source>J Dermatol.</source><year>2015</year><volume>42</volume><fpage>786</fpage><lpage>794</lpage><pub-id pub-id-type="doi">10.1111/1346-8138.12913</pub-id><?supplied-pmid 25917539?><pub-id pub-id-type="pmid">25917539</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mavilio</surname><given-names>F</given-names></name><name><surname>Pellegrini</surname><given-names>G</given-names></name><name><surname>Ferrari</surname><given-names>S</given-names></name><name><surname>Di Nunzio</surname><given-names>F</given-names></name><name><surname>Di Iorio</surname><given-names>E</given-names></name><name><surname>Recchia</surname><given-names>A</given-names></name><etal/></person-group><article-title>Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells</article-title><source>Nat Med.</source><year>2006</year><volume>12</volume><fpage>1397</fpage><lpage>1402</lpage><pub-id pub-id-type="doi">10.1038/nm1504</pub-id><?supplied-pmid 17115047?><pub-id pub-id-type="pmid">17115047</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Rosa</surname><given-names>L</given-names></name><name><surname>Carulli</surname><given-names>S</given-names></name><name><surname>Cocchiarella</surname><given-names>F</given-names></name><name><surname>Quaglino</surname><given-names>D</given-names></name><name><surname>Enzo</surname><given-names>E</given-names></name><name><surname>Franchini</surname><given-names>E</given-names></name><etal/></person-group><article-title>Long-term stability and safety of transgenic cultured epidermal stem cells in gene therapy of junctional epidermolysis bullosa</article-title><source>Stem Cell Reports.</source><year>2013</year><volume>2</volume><fpage>1</fpage><lpage>8</lpage><?supplied-pmid 24511464?><pub-id pub-id-type="pmid">24511464</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai-Cheong</surname><given-names>JE</given-names></name><name><surname>McGrath</surname><given-names>JA</given-names></name><name><surname>Uitto</surname><given-names>J</given-names></name></person-group><article-title>Revertant mosaicism in skin: natural gene therapy</article-title><source>Trends Mol Med.</source><year>2011</year><volume>17</volume><fpage>140</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1016/j.molmed.2010.11.003</pub-id><?supplied-pmid 21195026?><pub-id pub-id-type="pmid">21195026</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gostynski</surname><given-names>A</given-names></name><name><surname>Pasmooij</surname><given-names>AM</given-names></name><name><surname>Jonkman</surname><given-names>MF</given-names></name></person-group><article-title>Successful therapeutic transplantation of revertant skin in epidermolysis bullosa</article-title><source>J Am Acad Dermatol.</source><year>2014</year><volume>70</volume><fpage>98</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2013.08.052</pub-id><?supplied-pmid 24176523?><pub-id pub-id-type="pmid">24176523</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gostynski</surname><given-names>A</given-names></name><name><surname>Deviaene</surname><given-names>FC</given-names></name><name><surname>Pasmooij</surname><given-names>AM</given-names></name><name><surname>Pas</surname><given-names>HH</given-names></name><name><surname>Jonkman</surname><given-names>MF</given-names></name></person-group><article-title>Adhesive stripping to remove epidermis in junctional epidermolysis bullosa for revertant cell therapy</article-title><source>Br J Dermatol.</source><year>2009</year><volume>161</volume><fpage>444</fpage><lpage>447</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2133.2009.09118.x</pub-id><?supplied-pmid 19416258?><pub-id pub-id-type="pmid">19416258</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiritsi</surname><given-names>D</given-names></name><name><surname>Garcia</surname><given-names>M</given-names></name><name><surname>Brander</surname><given-names>R</given-names></name><name><surname>Has</surname><given-names>C</given-names></name><name><surname>Meijer</surname><given-names>R</given-names></name><name><surname>Esc&#225;mez</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Mechanisms of natural gene therapy in dystrophic epidermolysis bullosa</article-title><source>J Invest Dermatol.</source><year>2014</year><volume>134</volume><fpage>2097</fpage><lpage>2104</lpage><pub-id pub-id-type="doi">10.1038/jid.2014.118</pub-id><?supplied-pmid 24577406?><pub-id pub-id-type="pmid">24577406</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guerra</surname><given-names>L</given-names></name><name><surname>Dellambra</surname><given-names>E</given-names></name><name><surname>Panacchia</surname><given-names>L</given-names></name><name><surname>Paionni</surname><given-names>E</given-names></name></person-group><article-title>Tissue engineering for damaged surface and lining epithelia: stem cells, current clinical applications and available engineered tissues</article-title><source>Tissue Eng Part B Rev.</source><year>2009</year><volume>15</volume><fpage>91</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1089/ten.teb.2008.0418</pub-id><?supplied-pmid 19196154?><pub-id pub-id-type="pmid">19196154</pub-id></element-citation></ref></ref-list></back></article>